Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It never determines our rankings or which providers we cover. Read the full disclosure.
By The RX Index Editorial Team · Last verified: May 16, 2026 · Sources: CMS, KFF, FDA, Eli Lilly, state Medicaid bulletins, The RX Index state coverage dataset.
Published:
Does Medicaid Cover Zepbound? 2026 State Coverage, OSA Rules, and PA Steps
The short answer
Medicaid usually does not cover Zepbound for weight loss only unless your state Medicaid program covers obesity GLP-1s and your plan's prior-authorization criteria allow Zepbound. As of January 2026, 13 state Medicaid fee-for-service programs covered GLP-1 medications for obesity treatment under fee-for-service rules, according to KFF. That number is down from 16 in 2025 after California, New Hampshire, Pennsylvania, and South Carolina ended weight-loss-only coverage on January 1, 2026.
Here's the part most pages miss: Zepbound has a separate FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity. That creates a different Medicaid pathway in most states, since drugs for non-weight-loss indications are not in the optional/excludable category. People under 21, people with type 2 diabetes, and people in dual Medicare/Medicaid plans have their own paths too.
Here's the fastest possible map of where you stand:
| Your situation | Medicaid answer | What to do next |
|---|---|---|
| Zepbound for weight loss only | Usually no, unless your state is one of the 13 | Check your state's preferred drug list and PA criteria |
| Zepbound for moderate-to-severe OSA + obesity | Separate non-weight-loss pathway, PA-controlled | Ask your prescriber for sleep-study, AHI, and BMI documentation |
| You are under 21 | EPSDT may create a different review path | Ask Medicaid and prescriber about EPSDT medical-necessity review |
| You're in Medicaid managed care | Your MCO's formulary may differ from the state baseline | Check your MCO's PDL and call the number on your card |
| Your state recently changed coverage | Old approvals don't always carry over | Read your plan's current bulletin, not last year's |
| You have Medicaid + want the Zepbound Savings Card | Card is not available with government insurance | Compare true self-pay options instead |
| You have commercial or FEHB insurance instead | Medicaid rules don't apply | Use a free insurance coverage checker |
Last verified May 16, 2026. Coverage changes fast right now. Always confirm with your state Medicaid plan before assuming.
Check your Medicaid Zepbound path →
Pick your state, your diagnosis, and your plan type. We'll show you the pathway that matches your situation.
Get my personalized plan →No provider signup. No affiliate link. Free.
The real answer: does Medicaid cover Zepbound?
Answer in one paragraph: Medicaid may cover Zepbound, but not automatically. The answer depends on five things — your state, your plan type (fee-for-service or managed care), the diagnosis on the prescription, the prior-authorization criteria your plan uses, and whether you're under 21. There isn't one Medicaid coverage answer; there are state Medicaid programs, fee-for-service rules, and managed-care formularies inside each one.
Here's why the answer is so messy. Federal Medicaid rules generally require coverage of outpatient drugs from participating manufacturers for medically accepted indications. But there's a small list of drug categories Congress let states exclude. Drugs used "for weight loss" sit in that excluded category. So states can choose whether to pay for Zepbound when it's prescribed for obesity — and most don't.
When Zepbound is prescribed for a non-weight-loss FDA-approved use, the rules flip. The FDA approved Zepbound on December 20, 2024 for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, used with reduced-calorie diet and increased physical activity. That's not a weight-loss prescription. That's a sleep-apnea prescription. Federal Medicaid rules treat non-weight-loss FDA-approved indications differently from the optional weight-loss category.
The five Medicaid pathways on this page
- Obesity-only coverage — works in 13 states, not in the other 37.
- OSA + obesity coverage — a separate, non-weight-loss pathway that exists in most states, subject to PA.
- Diabetes coverage (via Mounjaro) — Mounjaro has the same active ingredient as Zepbound (tirzepatide) under a different FDA-approved label for type 2 diabetes.
- EPSDT (under-21) pathway — federal protection that can create a different medical-necessity review for minors.
- Cash-pay fallback — LillyDirect, TrumpRx, and telehealth services if no Medicaid pathway works.
Does Medicaid cover Zepbound for weight loss?
Answer capsule: In most states, no. As of January 2026, 13 state Medicaid fee-for-service programs covered GLP-1 medications for obesity treatment, according to KFF. That doesn't automatically mean Zepbound is preferred, covered, or available the same way in all 13 — Zepbound-specific coverage still depends on each state's preferred drug list, prior-authorization criteria, and managed-care plan rules. Four more states cut coverage on January 1, 2026, bringing the total down from 16.
The 13 states that still cover GLP-1s for obesity under Medicaid FFS
Even within these 13, coverage is rarely a green light. Obesity GLP-1s are typically subject to prior authorization, step therapy, and preferred-drug requirements. For example, North Carolina reinstated coverage in December 2025 but listed Wegovy as preferred and Zepbound as non-preferred, meaning patients usually need to try Wegovy first.
States that recently cut coverage
- California (Medi-Cal) — All weight-loss-only GLP-1 coverage for adults 21+ ended. Per Medi-Cal Rx, prior-authorization requests may still be submitted for Zepbound when used for OSA.
- Pennsylvania — All weight-loss GLP-1 coverage for adults 21+ ended. Coverage continues for other approved medical conditions. Under-21 patients still have coverage rights via EPSDT.
- New Hampshire — Weight-loss-only GLP-1 coverage eliminated. Other FDA-approved indications still covered under standard Medicaid rules.
- South Carolina — Weight-loss-only GLP-1 coverage eliminated.
The majority of adult Medicaid enrollees now live in states without a fee-for-service obesity GLP-1 pathway. See our Medicaid GLP-1 Coverage by State research page for adult-enrollee coverage reach by state.
Does Medicaid cover Zepbound for sleep apnea?
Answer capsule: Zepbound's FDA-approved OSA indication creates a separate non-weight-loss Medicaid pathway. Coverage is generally stronger for non-excluded medically accepted indications than for weight-loss-only use, but approval still depends on your state or MCO's formulary, prior-authorization criteria, and documentation. Even states that cut weight-loss-only coverage in 2026 — including California — have kept the OSA pathway open for Zepbound with PA.
This is the most important section of this guide. Most people searching "does Medicaid cover Zepbound" don't realize there's a second front door.
What "moderate-to-severe OSA" means in practice
Doctors diagnose OSA with a sleep study (polysomnography, or PSG; the home version is HSAT). Severity is measured by your AHI — Apnea-Hypopnea Index. The numbers your plan will look for:
- AHI 5–14: mild OSA — usually not enough for Zepbound coverage
- AHI 15–29: moderate OSA — typically meets the Zepbound threshold
- AHI 30+: severe OSA — clearly meets the threshold
What state Medicaid plans actually ask for
Real Medicaid prior authorization forms for Zepbound-for-OSA are public. Patterns from Louisiana and Oklahoma forms show:
- Confirmed diagnosis of moderate-to-severe OSA (AHI ≥ 15 typically)
- Recent sleep study results (timing varies by state — check your plan's form)
- BMI of 30 or higher, measured recently
- Whether you've tried or are using CPAP/BiPAP, and how it's going
- A reduced-calorie diet and physical activity plan
- Confirmation you're not already on another GLP-1 receptor agonist
Why OSA coverage can still be denied
- Sleep study is too old for that plan's standard
- AHI is documented but below the threshold the plan uses
- BMI isn't current (often required within 30 days)
- The PA form is missing CPAP history or lifestyle plan
- Documentation didn't include moderate-to-severe severity clearly
An OSA denial may be a documentation problem, a PA-criteria problem, or a plan-rule problem. The written denial tells you which. Fix what the letter calls out and you can often resubmit.
Build my OSA prior authorization checklist →
A free, printable list of every item your prescriber should include before submitting.
Get the checklist →No provider signup. No email required.
Which states cover Zepbound with Medicaid in 2026?
Answer capsule: For weight-loss-only use under Medicaid fee-for-service, 13 state programs cover GLP-1 medications like Zepbound for obesity: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin. For sleep apnea, Zepbound's separate FDA-approved OSA indication gives it a different coverage pathway outside obesity-only rules — but the claim still has to satisfy your plan's PA criteria.
Bucket 1: Covers GLP-1s for obesity under Medicaid FFS
Delaware · Kansas · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · North Carolina · Rhode Island · Tennessee · Utah · Virginia · Wisconsin
If you're in one of these, you have an obesity-only pathway with prior authorization. Still check your specific managed-care plan.
Bucket 2: Covers some weight-loss drug but not GLP-1s for obesity
Connecticut · Louisiana · New Hampshire · New Mexico · North Dakota · Pennsylvania · Texas
These states might cover a non-GLP-1 weight-loss medication like orlistat. Your real path here is the OSA pathway, the diabetes pathway via Mounjaro, or the under-21 EPSDT pathway.
Bucket 3: No GLP-1 obesity coverage under Medicaid FFS
Alabama · Alaska · Arizona · Arkansas · California · Colorado · DC · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kentucky · Maine · Maryland · Montana · Nebraska · Nevada · New Jersey · New York · Ohio · Oklahoma · Oregon · South Carolina · South Dakota · Vermont · Washington · West Virginia · Wyoming
If you're here, the obesity-only door is closed for adults. Look at OSA, diabetes via Mounjaro, EPSDT (under 21), or cash-pay.
Recent state changes worth knowing
| State | Change | Date | What it means |
|---|---|---|---|
| California | Ended adult weight-loss GLP-1 coverage | Jan 1, 2026 | Zepbound PA may be submitted for OSA; other GLP-1 indication paths may apply to different products |
| Pennsylvania | Ended adult weight-loss GLP-1 coverage | Jan 1, 2026 | Under-21 still covered via EPSDT; other indications covered |
| New Hampshire | Ended adult weight-loss GLP-1 coverage | Jan 1, 2026 | Other indications still covered |
| South Carolina | Ended weight-loss GLP-1 coverage | Jan 1, 2026 | Other indications still covered |
| Michigan | Tightened obesity GLP-1 coverage | Jan 1, 2026 | Stricter medical-necessity criteria; diabetes/CVD/OSA continue |
| North Carolina | Reinstated coverage after brief cut | Dec 12, 2025 | Wegovy preferred; Zepbound non-preferred |
| Massachusetts | Zepbound PA criteria active on drug list | May 13, 2026 | July 1, 2026 anti-obesity GLP-1 management changes announced |
For the full 50-state table with drug-level detail and source links, see our Medicaid GLP-1 Coverage by State research page. It updates monthly.
What if I have Medicaid managed care instead of fee-for-service?
Answer capsule: Your state's fee-for-service list is only the baseline. Most Medicaid enrollees are in a managed care organization (MCO), and your MCO's formulary, prior-authorization rules, and implementation timing can differ from the state FFS rules in either direction.
Two readers in the same state can get two different answers. A member in Florida with Sunshine Health (Centene) looks up Zepbound on the Sunshine Health PDL. A member in Florida with Aetna Better Health looks up Zepbound on a different formulary. Same state. Same FFS baseline (which currently does not cover obesity GLP-1s in Florida). But each MCO can structure its formulary and PA rules differently.
What to actually do
- Find the name of your Medicaid plan. It's on the front of your insurance card, not just "Medicaid."
- Call the member services number on the back. Ask: "Is Zepbound on my formulary? Is it preferred or non-preferred? What's the prior authorization criteria?"
- Ask the same question for OSA. Some MCOs handle OSA-pathway requests through a different process than weight-loss requests.
- Get the answer in writing if possible. A printed/emailed formulary entry protects you when your prescriber submits the PA.
How to get Zepbound approved by Medicaid (the PA playbook)
Answer capsule: Getting Zepbound approved through Medicaid comes down to a clean prior authorization with the right diagnosis, the right documentation, and the right paperwork sequence. One common, fixable reason PAs fail is missing or outdated documentation.
Step 1 — Find your plan's preferred drug list (PDL)
Search your state's name plus "Medicaid preferred drug list" or "Medicaid PDL." If you're in a managed care organization, your MCO has its own formulary. You're looking for two things: Is Zepbound or tirzepatide listed? Is it preferred, non-preferred, or excluded?
Step 2 — Confirm the diagnosis you're submitting under
Zepbound is approved for two things: weight loss in adults with obesity (or overweight with weight-related conditions) and moderate-to-severe OSA in adults with obesity. Decide with your prescriber which is the medically accurate fit.
Step 3 — Ask your prescriber exactly what they're submitting
Use this short script with the doctor's office:
"I'm trying to get Zepbound covered by Medicaid. Before you submit the prior authorization, can you tell me: what diagnosis code are you using? What's my documented BMI? Is my sleep study or comorbidity documentation attached? Does our state need a step-therapy attempt first?"
Step 4 — Submit the PA, then wait — don't fill the script first
If you walk into the pharmacy and get quoted $1,000+, it usually means the PA hasn't been approved, hasn't been submitted, or the claim was denied. Confirm with your plan whether the PA is pending, approved, or denied before paying cash.
Step 5 — Save every letter
If you get a denial, the letter will tell you exactly which criterion failed and how long you have to appeal. Photograph it, scan it, keep it.
Build my Zepbound Medicaid PA prep sheet →
Fill in your state, plan, diagnosis, and BMI. We'll generate a checklist your doctor's office can use.
Open the prep sheet →What does a Medicaid Zepbound prior authorization usually require?
Answer capsule: Medicaid prior authorization for Zepbound typically requires documented BMI within 30 days, a qualifying diagnosis, 3–6 months of documented diet and physical activity efforts, prior medication attempts where required by step therapy, and confirmation that no other tirzepatide or GLP-1 receptor agonist is being used at the same time.
The obesity-pathway checklist
- BMI ≥ 30, or ≥ 27 with a weight-related condition
- BMI measured within the last 30 days
- Documented history of diet and exercise (3–6 months)
- List of previous weight-loss medications tried
- Confirmation you're not on another GLP-1
- In some states: step therapy through a preferred drug (Wegovy)
The OSA-pathway checklist
- Confirmed moderate-to-severe OSA (AHI ≥ 15)
- Sleep study or polysomnography results
- Current BMI ≥ 30
- Current CPAP or BiPAP status
- A reduced-calorie diet and physical activity plan
- Confirmation no other tirzepatide is being used
Continuation criteria
After your first approval, plans usually want a weight-loss threshold met (typically 5% of starting body weight by month 6 or 12), continued symptom improvement for OSA, and documented follow-up visits.
Red flags that slow approval
- Outdated sleep study (check your plan's specific timing rule)
- BMI documented outside the 30-day window
- A "weight loss" diagnosis code submitted in a state that excludes weight loss
- Missing step-therapy documentation
- Trying to bill obesity-pathway in a state that requires OSA documentation
Most denials are not "the plan hates this drug." They're a fillable piece of paper that wasn't fully filled out.
What if Medicaid denies Zepbound? Your 4-step appeal path
Answer capsule: A Medicaid denial isn't automatically the end. Federal law guarantees Medicaid members the right to appeal, and your written Notice of Action gives the deadline.
Step 1 — Get the denial in writing. Call the number on your card and request a written denial. The letter has to tell you the specific reason and your appeal deadline.
Step 2 — Identify the denial type. Each category has a different play:
| Denial type | What it means | Best move |
|---|---|---|
| Plan exclusion | The drug isn't covered for your use case in this plan | Switch pathway (OSA, diabetes, EPSDT) or move to cash-pay |
| PA denial — missing info | Documentation didn't include something required | Resubmit with the missing item |
| Step therapy | You need to try a preferred drug first | Try the preferred drug or document why it's inappropriate |
| Non-preferred drug | Zepbound is covered but not preferred over an alternative | Switch to the preferred drug or document medical necessity for Zepbound |
| Continuation criteria not met | Not hitting the weight-loss threshold for renewal | Document partial progress and provider judgment |
Step 3 — Resubmit or appeal. If documentation is missing, your prescriber can resubmit within days. If you're appealing a policy denial, federal rules require a fair-hearing opportunity. California's Medi-Cal notice, for example, says members generally have 90 days from the Notice of Action date, with a shorter window (often 10 days) to keep benefits active during the appeal.
Step 4 — Request a fair hearing if needed. Every state has a Medicaid fair hearing process. You can request it yourself — no lawyer needed. If the plan made a documentation error or misapplied a criterion, fair hearings often reverse denials.
Create my denial-response checklist →
Tell us the denial reason and we'll tell you whether to resubmit, appeal, switch pathway, or move to a cash-pay fallback.
Open the checklist →Can you use the Zepbound Savings Card with Medicaid?
Answer capsule: No. Per Eli Lilly's published terms, the Zepbound Savings Card excludes anyone enrolled in Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE/CHAMPUS, or any state prescription drug assistance program.
This is the single biggest source of confusion we see. The "as little as $25/month" ads everywhere lead a lot of Medicaid members to assume the discount applies to them. It doesn't.
You have three real legal options if your state Medicaid won't cover Zepbound:
- Try to find another Medicaid pathway — OSA, diabetes via Mounjaro, EPSDT if under 21, or an appeal
- Pay cash through LillyDirect's Self-Pay program — KwikPen pricing starts at $299/month for the 2.5 mg dose
- Pay through a different cash-pay route — TrumpRx or a telehealth service
How much does Zepbound cost if Medicaid won't cover it?
Answer capsule: The cheapest legal cash-pay route is Eli Lilly's Self-Pay Journey Program through LillyDirect. KwikPen pricing: $299/month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg when the Self-Pay Journey terms apply — which on the 7.5 mg and higher doses requires a refill within 45 days of the previous delivery. Miss the window: $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg. TrumpRx averages about $346/month. Retail pharmacy without any program is approximately $1,086/month.
Brand-name Zepbound cash-pay price table
| Path | 2.5 mg | 5 mg | 7.5 mg–15 mg | Notes |
|---|---|---|---|---|
| LillyDirect Self-Pay Journey (KwikPen) | $299 | $399 | $449 with 45-day refill | Regular price if you miss the 45-day window: $499 (7.5 mg), $699 (10/12.5/15 mg) |
| LillyDirect Self-Pay Journey (single-dose vial) | $299 | $399 | $449 with 45-day refill | Vials require drawing from a syringe |
| TrumpRx | ~$299 lowest dose | — | ~$346 average | Cash-pay only |
| Retail pharmacy (no assistance) | ~$1,086 | ~$1,086 | ~$1,086 | KwikPen list price |
| Ro (brand-name Zepbound) | LillyDirect-matched | LillyDirect-matched | LillyDirect-matched | + Ro Body membership: $39 first month, then $149/mo (or $74/mo annual) |
| Sesame Care (Zepbound vials via LillyDirect) | $299 | $399 | $449 | + provider/program pricing separate |
| Sesame Care (Zepbound KwikPen) | $299 | $399 | $499 (7.5 mg) / $699 (10–15 mg) | + provider/program pricing separate |
Last verified May 16, 2026. Sources: Eli Lilly Self-Pay Journey Program terms; LillyDirect terms; trumprx.gov; White House fact sheet (Nov 2025); Ro pricing page; Sesame Care Zepbound page.
Why the 45-day refill window matters
The $449 LillyDirect price on the 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses only holds if you refill within 45 days of your previous delivery. Miss it on the 7.5 mg dose and you pay $499. Miss it on the 10 mg, 12.5 mg, or 15 mg doses and you pay $699. Set a calendar reminder around day 30–35 of every fill.
What this means if you're truly on a Medicaid budget
Let's be honest: $299–$449 a month is a lot of money for someone on Medicaid. If your household budget can't absorb that, paying out of pocket for brand-name Zepbound is probably not realistic. Your better moves are:
- Push harder on the OSA pathway if it's medically accurate
- Ask about Mounjaro if you have type 2 diabetes
- Use the EPSDT pathway if you're under 21
- Wait for your state's possible BALANCE Model participation
- File a fair-hearing appeal if you believe your denial was wrong
If Medicaid won't cover Zepbound, what are your real alternatives?
Answer capsule: Your best alternative depends on why Medicaid said no. If it's documentation, fix it and resubmit. If it's a state exclusion, look at OSA or EPSDT pathways. If you have type 2 diabetes, Mounjaro has the same active ingredient under a different FDA-approved label and is generally covered for diabetes. If none of those work and you can afford it, brand-name cash-pay through Ro, Sesame Care, or LillyDirect is a legitimate path.
Path A — You have type 2 diabetes
Ask your prescriber about Mounjaro. Mounjaro has the same active ingredient as Zepbound (tirzepatide) under a different FDA-approved label for type 2 diabetes. Medicaid coverage for diabetes indications is generally required, though state plans may apply diagnosis-code requirements, prior authorization, quantity limits, and preferred-drug rules.
Path B — You have moderate-to-severe OSA
See the sleep apnea section above. Document the OSA, get the sleep study results in your record, and have your prescriber submit the PA under the OSA indication. This works in most states even after the 2026 weight-loss-only cuts.
Path C — You're under 21
Federal EPSDT rules require Medicaid to cover medically necessary care for people under 21. EPSDT can create a separate medical-necessity review path even when adult coverage is excluded. Pennsylvania kept under-21 weight-loss GLP-1 coverage when adult coverage was cut on January 1, 2026.
Path D — You're a dual-eligible (Medicare + Medicaid)
Read our companion guide: Does Medicare Cover Zepbound? The Medicare GLP-1 Bridge is scheduled to begin July 1, 2026 and run through December 31, 2027, offering $50/month copays for eligible Medicare Part D beneficiaries. The Bridge covers Zepbound KwikPen only — vials and single-dose pens are not included.
Path E — You have commercial or marketplace insurance
If Medicaid isn't your only coverage, commercial insurance plus the Zepbound Savings Card (allowed for commercially insured patients) can drop cost to as low as $25/month — subject to monthly and annual caps in Lilly's terms.
Path F — You've decided cash-pay is your path
For brand-name Zepbound on a cash-pay basis, Ro is built specifically for this. Ro carries Zepbound (tirzepatide) and Foundayo (orforglipron). Ro's Zepbound KwikPen cash pricing matches LillyDirect/TrumpRx — listed at $299 first month and $399–$449/month thereafter. Ro Body membership is $39 for the first month, then as low as $74/month with annual plan (or $149/month monthly), separate from medication cost.
If you want broader provider choice and prefer a per-visit model, Sesame Care carries brand-name Zepbound and several other FDA-approved GLP-1s with transparent visit pricing.
If you don't need any coverage help, LillyDirect may be cheaper — no membership fee, but you'll do the prior-auth work yourself.
Check brand-name Zepbound pricing and coverage options on Ro →
Free GLP-1 Insurance Coverage Checker. Brand-name Zepbound at LillyDirect-matched pricing. Best for readers who've ruled out Medicaid for Zepbound and either want help navigating commercial or FEHB coverage, or have decided cash-pay is their path.
Check eligibility on Ro →If you're on Medicaid with no other insurance and can't afford ~$300–$500/month, this isn't the right next step — keep working the Medicaid pathways above.
Will the 2026 BALANCE Model change Medicaid Zepbound coverage?
Answer capsule: Possibly, but not automatically. CMS's BALANCE Model — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — can launch in Medicaid as early as May 2026 for participating state Medicaid agencies. It's a voluntary federal program that negotiates GLP-1 drug pricing and coverage terms with manufacturers on behalf of states that opt in.
What BALANCE actually does
CMS negotiates with eligible GLP-1 manufacturers (including Eli Lilly for Zepbound and Novo Nordisk for Wegovy) to set lower drug prices for participating states. States that opt in agree to standardized coverage criteria. BALANCE pairs GLP-1 access with lifestyle supports provided by the manufacturer.
What BALANCE does not guarantee
BALANCE is voluntary at three levels: manufacturers, states, and managed care plans all have to choose to participate. Some states facing budget pressure may not opt in. Even when a state joins, individual coverage still depends on clinical criteria and prior authorization.
Don't confuse BALANCE with the Medicare Bridge
The Medicare GLP-1 Bridge is a separate program — Medicare only, not Medicaid. It's scheduled to begin July 1, 2026 and run through December 31, 2027. It offers a $50/month copay for eligible Medicare Part D beneficiaries. If you have Medicare alongside Medicaid (dual-eligible), the Bridge may be the right primary route. Details: Does Medicare Cover Zepbound?
Watch your state Medicaid agency announcements through fall 2026. KFF and our own state tracker update monthly with participation news.
What we verified
High-risk coverage, pricing, FDA-status, and provider claims on this page were checked against the sources below. Verified May 16, 2026.
| Claim | Source |
|---|---|
| 13 state Medicaid FFS programs covered GLP-1s for obesity (Jan 2026) | KFF — Medicaid Coverage of and Spending on GLP-1s |
| Specific 13 states named | Pew Research Center / KFF |
| Optional/excludable category for weight-loss drugs | 42 U.S. Code § 1396r-8 (LII) |
| FDA approved Zepbound for OSA on Dec 20, 2024 | FDA press release |
| CA Medi-Cal weight-loss GLP-1 coverage ended Jan 1, 2026 | Medi-Cal Rx GLP-1 Changes notice |
| PA Medicaid ended adult weight-loss GLP-1 coverage Jan 1, 2026 | PHLP Pennsylvania bulletin |
| Michigan tightened obesity GLP-1 coverage Jan 1, 2026 | University of Michigan Medical School Expert Q&A |
| NC Medicaid reinstated obesity GLP-1 coverage Dec 12, 2025; Zepbound non-preferred | NC Medicaid bulletin |
| LillyDirect Self-Pay Journey pricing ($299/$399/$449 with 45-day refill) | Eli Lilly Self-Pay Journey terms |
| Regular KwikPen prices ($499 for 7.5 mg; $699 for 10/12.5/15 mg) | Zepbound savings page |
| TrumpRx Zepbound ~$346 average | AJMC; White House fact sheet |
| Zepbound Savings Card excludes government insurance | zepbound.lilly.com/savings terms |
| BALANCE Model Medicaid opt-in opens May 2026 | CMS.gov BALANCE Model page |
| Medicare GLP-1 Bridge Jul 1, 2026 – Dec 31, 2027 | CMS Medicare GLP-1 Bridge page |
| Ro Body membership pricing ($39 first month, $149/mo or $74/mo annual) | Ro pricing page |
| Sesame Care Zepbound dose-group pricing | Sesame Care Zepbound page |
Frequently asked questions
- Does Medicaid cover Zepbound?
- Medicaid may cover Zepbound, but coverage depends on your state, your plan, your diagnosis, and prior authorization. For weight loss only, 13 state Medicaid fee-for-service programs cover GLP-1s like Zepbound for obesity as of January 2026. For moderate-to-severe sleep apnea with obesity, the FDA-approved OSA indication creates a separate non-weight-loss pathway, subject to PA.
- Does Medicaid cover Zepbound for weight loss?
- In most states, no. Federal Medicaid law lets states exclude drugs used for weight loss from required coverage. As of January 2026, 13 state Medicaid FFS programs cover GLP-1s like Zepbound for obesity: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin.
- Does Medicaid cover Zepbound for sleep apnea?
- Generally, with prior authorization. The FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity on December 20, 2024. Because OSA is a non-weight-loss FDA-approved indication, federal Medicaid rules treat it differently from the optional weight-loss category — plans typically have a coverage pathway, though PA criteria still apply.
- Which states cover Zepbound with Medicaid in 2026?
- For weight-loss coverage under fee-for-service Medicaid: Delaware, Kansas, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Utah, Virginia, and Wisconsin. For OSA coverage, the list is broader since OSA is a non-weight-loss FDA-approved indication, though each plan applies its own PA rules.
- Can I use the Zepbound Savings Card with Medicaid?
- No. Per Lilly's terms, the Zepbound Savings Card excludes anyone enrolled in Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE/CHAMPUS, or any state prescription drug assistance program.
- What if Medicaid denies Zepbound?
- Read the written denial first. If documentation is missing, your prescriber can resubmit. If the denial is about policy interpretation, you have appeal rights — your Notice of Action gives the deadline (often around 90 days). Every state has a Medicaid fair-hearing process. If your state truly excludes Zepbound for your use case, look at the OSA pathway, the Mounjaro pathway for diabetes, the EPSDT pathway if under 21, or a cash-pay route.
- Does Medi-Cal cover Zepbound?
- California Medi-Cal stopped covering GLP-1 medications for weight loss in adults 21 and older effective January 1, 2026. For Zepbound specifically, Medi-Cal allows PA requests when Zepbound is used for OSA. Don't assume Zepbound is covered for type 2 diabetes, cardiovascular disease, or MASH on Medi-Cal — those pathways may apply to different GLP-1 products. Under-21 patients still have coverage rights via EPSDT.
- Does NC Medicaid cover Zepbound?
- North Carolina Medicaid reinstated GLP-1 coverage for weight management effective December 12, 2025. Wegovy is listed as preferred and Zepbound is non-preferred, meaning patients usually need to try Wegovy first or document why Wegovy isn't appropriate.
- Does Medicaid cover tirzepatide?
- Yes — for type 2 diabetes. Medicaid coverage for GLP-1s prescribed for diabetes is generally required, though plans may apply diagnosis-code rules, prior authorization, quantity limits, and preferred-drug requirements. Mounjaro is tirzepatide approved for type 2 diabetes; Zepbound is tirzepatide approved for obesity and for moderate-to-severe OSA with obesity. Same active ingredient, different FDA-approved labels and indications.
- What's the cheapest legal way to get Zepbound without Medicaid coverage?
- LillyDirect's Self-Pay Journey Program: $299/month for the 2.5 mg dose, $399/month for 5 mg, and $449/month for 7.5 mg through 15 mg when the Self-Pay Journey terms apply (which on 7.5 mg and higher doses require refill within 45 days of the previous delivery). Miss that window and the regular KwikPen price is $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg. TrumpRx is roughly $346/month on average. Retail pharmacy without any program is approximately $1,086/month.
- When will the BALANCE Model start covering Zepbound through Medicaid?
- State Medicaid agencies can begin opting into BALANCE in May 2026. Whether your state covers Zepbound through BALANCE depends on whether your state opts in and the terms CMS negotiates with Eli Lilly. The program is voluntary at every level — manufacturers, states, and plans.
- Is compounded tirzepatide the same as Zepbound?
- No. Compounded tirzepatide is not Zepbound and is not FDA-approved. The FDA notes that compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before marketing. Tirzepatide is not currently on FDA's drug-shortage list, and FDA's post-shortage enforcement discretion periods for GLP-1 compounding copies have ended. This page covers Medicaid coverage for brand-name FDA-approved Zepbound, not compounded tirzepatide.
Your next step
If you're in one of the 13 covered states (or your OSA case is documented): Print the prior-authorization prep sheet, hand it to your doctor's office, and have them submit the PA this week. Don't fill the script at retail before the PA is approved.
If you're in a state that doesn't cover Zepbound for obesity: Look at the OSA pathway first if it medically fits. Then Mounjaro if you have type 2 diabetes. Then EPSDT if you're under 21. Then file an appeal if your denial looks wrong. Then watch for BALANCE participation in your state.
If none of those apply and you've decided cash-pay is your path: LillyDirect is the cheapest legal brand-name route at $299–$449/month with the 45-day refill rule. Ro is the easiest navigated path if commercial or FEHB coverage might exist. Sesame Care is the right choice if you want provider variety and per-visit pricing.
Still not sure which Zepbound pathway is right for you?
Take our free 60-second matching quiz. We'll sort Medicaid, OSA, EPSDT, dual-eligible, commercial insurance, and cash-pay paths based on your state, your conditions, and your insurance — and we'll show you what to ask your doctor and your plan.
Get my Zepbound action plan →Free. No signup. Takes about a minute.
About this guide
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. This guide was built from primary sources: FDA approvals and labels, CMS innovation model documentation, federal Medicaid law (42 U.S. Code § 1396r-8), KFF and Pew policy tracking, official state Medicaid notices and prior authorization forms (including Medi-Cal Rx, NC Medicaid, Louisiana Medicaid, Oklahoma Medicaid, MassHealth), Eli Lilly's pricing and savings-card terms, and our own monthly verification of state Medicaid bulletins.
We do not provide medical advice. Talk to your prescriber about whether Zepbound is right for you, and verify all coverage details directly with your state Medicaid program or managed-care plan before relying on them. Drug coverage, pricing, and program terms can change without notice.
Editorial standards and methodology: therxindex.com/editorial-standards · therxindex.com/methodology
Related guides
- Medicaid GLP-1 Coverage by State (full 50-state tracker)
- Does Medicare Cover Zepbound? 3 Paths
- Find My GLP-1 Path (quiz)
Last verified: May 16, 2026. By The RX Index Editorial Team.